Figure 1



Stage II or III breast cancer (Her2/neu neg) T ≥ 3 cm No IBC
Bevacizumab Low or Std dose
Placebo
TAC x 6 followed by surgery
Unblind
Bev. group: Bev x8
Placebo Group: No further tx
Core biopsy and MRI pre-bevacizumab and 14 days after bevacizumab
Bevacizumab: 7.5 mg/kg or 15 mg/kg

Figure 2



90 patients randomized
TAC + placebo
N= 32
TAC + bev 7.5
N=28
TAC + bev 15
N=30
Off study prior to surgery
N=4
N=2
N=6
Completed Study Treatment
N=28
N=26
N=24

Figure 3




Figure 4



Dll4/CD144
Ratio to Predose
2.0
1.5
1.0
0.5
0.0
p-0.014
Placebo
bev (15mg/kg)
bev (7.5mg/kg)

Figure 5



ANGPT2
2.0
1.5
1.0
0.5
0.0
Placebo
bev (15mg/kg)
bev (7.5mg/kg)
Placebo
bev

Figure 6



Factor V
Ratio to Predose
15
10
5
0
Placebo
bev (15mg/kg)
bev (7.5mg/kg)
Placebo
bev

Figure 7





Figure 8


NOS2 expression decreases upon bevacizumab treatment
*P=0.0045
Ratio to Predose
2.5
2.0
1.5
1.0
0.5
0.0
Placebo
bevacizumab